Wendell Wierenga - 17 Aug 2021 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
Director
Signature
/s/ Gerald T. Proehl, Attorney-in-Fact
Issuer symbol
DRMA
Transactions as of
17 Aug 2021
Net transactions value
$0
Form type
4
Filing time
17 Aug 2021, 12:45:43 UTC
Previous filing
12 Aug 2021
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRMA Common Stock Conversion of derivative security +8,163 +167% 13,041 17 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRMA Series 1d Preferred Stock Conversion of derivative security $0 -55,078 -100% $0.000000* 0 17 Aug 2021 Common Stock 8,163 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.